Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T94918
|
||||
Target Name |
COVID-19 RNA-directed RNA polymerase (RdRp)
|
||||
Synonyms |
COVID-19 Pol; COVID-19 nsp12
|
||||
Gene Name |
COVID-19 rep; COVID-19 1a-1b
|
||||
Target Status |
Target in Phase 3 Trial
|
[1] | |||
Disease | [+] 1 Target-related Diseases | + | |||
1 | COVID-19 [ICD-11: 1D6Y] | ||||
Function |
Responsible for replication and transcription of the viral RNA genome.
|
||||
BioChemical Class |
Coronaviruses polyprotein 1ab family
|
||||
UniProt ID | |||||
EC Number |
EC 2.7.7.48
|
||||
Sequence |
SADAQSFLNRVCGVSAARLTPCGTGTSTDVVYRAFDIYNDKVAGFAKFLKTNCCRFQEKD
EDDNLIDSYFVVKRHTFSNYQHEETIYNLLKDCPAVAKHDFFKFRIDGDMVPHISRQRLT KYTMADLVYALRHFDEGNCDTLKEILVTYNCCDDDYFNKKDWYDFVENPDILRVYANLGE RVRQALLKTVQFCDAMRNAGIVGVLTLDNQDLNGNWYDFGDFIQTTPGSGVPVVDSYYSL LMPILTLTRALTAESHVDTDLTKPYIKWDLLKYDFTEERLKLFDRYFKYWDQTYHPNCVN CLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQDVN LHSSRLSFKELLVYAADPAMHAASGNLLLDKRTTCFSVAALTNNVAFQTVKPGNFNKDFY DFAVSKGFFKEGSSVELKHFFFAQDGNAAISDYDYYRYNLPTMCDIRQLLFVVEVVDKYF DCYDGGCINANQVIVNNLDKSAGFPFNKWGKARLYYDSMSYEDQDALFAYTKRNVIPTIT QMNLKYAISAKNRARTVAGVSICSTMTNRQFHQKLLKSIAATRGATVVIGTSKFYGGWHN MLKTVYSDVENPHLMGWDYPKCDRAMPNMLRIMASLVLARKHTTCCSLSHRFYRLANECA QVLSEMVMCGGSLYVKPGGTSSGDATTAYANSVFNICQAVTANVNALLSTDGNKIADKYV RNLQHRLYECLYRNRDVDTDFVNEFYAYLRKHFSMMILSDDAVVCFNSTYASQGLVASIK NFKSVLYYQNNVFMSEAKCWTETDLTKGPHEFCSQHTMLVKQGDDYVYLPYPDPSRILGA GCFVDDIVKTDGTLMIERFVSLAIDAYPLTKHPNQEYADVFHLYLQYIRKLHDELTGHML DMYSVMLTNDNTSRYWEPEFYEAMYTPHTVLQ |
||||
Drugs and Modes of Action | |||||
Drugs in Phase 3 Trial | [+] 2 Drugs in Phase 3 Trial | + | |||
1 | Favipiravir | Drug Info | Phase 3 Trial | COVID-19 | [2], [3] |
2 | Remdesivir | Drug Info | Phase 3 Trial | COVID-19 | [4] |
Drugs in Phase 2 Trial | [+] 1 Drugs in Phase 2 Trial | + | |||
1 | Lopinavir + ritonavir + ribavirin + interferon beta-1b | Drug Info | Phase 2 Trial | COVID-19 | [5] |
Drugs in Phase 1 Trial | [+] 1 Drugs in Phase 1 Trial | + | |||
1 | Galidesivir | Drug Info | Phase 1 Trial | COVID-19 | [6] |
Investigative agents | [+] 3 Investigative agents | + | |||
1 | Penciclovir | Drug Info | Investigative | COVID-19 | [7], [8] |
2 | Anidulafungin | Drug Info | Investigative | COVID-19 | [8] |
3 | Suramin | Drug Info | Investigative | COVID-19 | [8] |
Mode of Action | [+] 2 Modes of Action | + | |||
Inhibitor | [+] 6 Inhibitor drugs | + | |||
1 | Favipiravir | Drug Info | [9], [10] | ||
2 | Remdesivir | Drug Info | [1], [7] | ||
3 | Lopinavir + ritonavir + ribavirin + interferon beta-1b | Drug Info | [10] | ||
4 | Anidulafungin | Drug Info | [8] | ||
5 | Penciclovir | Drug Info | [7], [8] | ||
6 | Suramin | Drug Info | [8] | ||
Blocker | [+] 1 Blocker drugs | + | |||
1 | Galidesivir | Drug Info | [11] |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.